InterMune Positive On Pirfenidone Despite Mixed Study Results
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
InterMune was left with a mixed bag when it released its major Phase III program of pirfenidone in idiopathic pulmonary fibrosis, which yielded conflicting primary endpoint results. But the company thinks there are enough tricks in that bag to win FDA approval